Abstract
Maturity-onset diabetes of the young (MODY) is the most common monogenetic diabetes, which is easily misdiagnosed. We describe the first Chinese MODY4 family with a novel mutation, indicating that MODY4 cannot be excluded in early-onset obese diabetes, and pancreatic exocrine dysfunction could be present in MODY4.
Introduction
Maturity-onset diabetes of the young (MODY) is caused by autosomal dominant mutations, and 14 MODY subtypes have been identified at present. The correct diagnosis provides accurate genetic counseling and may help with appropriate management. However, the clinical overlap between MODY and type 2 diabetes (T2D) or type 1 diabetes (T1D) makes it difficult to diagnose in an accurate and timely manner.
The US SEARCH for Diabetes in the Youth study reported that most MODY cases were misdiagnosed as type 1 (36%) or type 2 diabetes (51%) (). Liu et al. suggested that, without genetic diagnosis, the clinical misdiagnosis rate of MODY2 was 85.4% (47/55) in China, and 58.2% (32/55) of MODY2 patients received incorrect treatment (). MODY1-3 are the most common forms of MODY. MODY4 is a rare type of MODY that is caused by heterozygous PDX1 gene mutations. PDX1 encodes the insulin promoter factor-1 (IPF1), a transcription factor that plays a critical role in pancreatic and beta cell development and function (). Previous studies of heterozygous carriers of PDX1 mutations suggest that MODY4 is a relatively mild disorder of glucose intolerance characterized by diminished insulin secretion (–). In the present report, we describe a 14-year-old Chinese boy who was misdiagnosed with T1D and ultimately diagnosed with MODY4 after genetic analysis. This is the first reported case of MODY4 in China, which indicated that obese MODY4 could be disguised.
Case Report
The proband was born in 2005 with a birth weight of 3,900 g. His mother denied gestational diabetes mellitus. The proband was diagnosed with type 1 diabetes (T1D) in October 2018, with positive uric ketone and fasting blood glucose (FBG) 20 mmol/L. At diagnosis, his height was 181 cm, and his weight was 80 kg, with a body mass index (BMI) of 24.4 kg/m2. He was treated with a total dose of 23 units of insulin per day. He presented to the Department of Metabolism & Endocrinology in Peking Union Medical College Hospital (PUMCH) 1 month after the onset of diabetes. His fasting C-peptide (FCP) was 1.10 ng/ml, and 2 h postprandial C-peptide (2hCP) was 3.36 ng/ml, with FBG 6.4 mmol/l and 2 h postprandial glucose (2hPG) 8.1 mmol/l. Glycated hemoglobin (HbA1c) was 10.7% and glycated albumin (GA%) was 23.5%. The patient was negative for the glutamic acid decarboxylase antibody (GAD-Ab), insulinoma-associated protein-2 antibody (IA2-Ab), and islet cell antibody (ICA). Insulin was discontinued, and he was treated with metformin since then. However, approximately half a month later, he experienced occasional hypoglycemia with only metformin 0.5 g QD. FBG was 5.3 mmol/L, and 2hPG 5.1 was mmol/L. No oral antidiabetic medications were prescribed for him since December 2018.We learned that he continued to run every day since the diagnosis of diabetes. His weight was only 63 kg, and his BMI was 18.8 kg/m2 when hypoglycemia occurred. However, the proband had occasional abdominal pain since the onset of diabetes. Although no abnormality was revealed by abdominal ultrasound, his serum amylase level was 34 U/L (normal range: 25–115), and his serum lipase level was 63 U/L (normal range: 73–393).
The father of the proband was found to be hyperglycemic (FBG 10 mmol/l) at the age of 34. His BMI was 25.9 kg/m2 at diagnosis. Glucose was controlled with metformin 0.25 g TID. His FBG is 7.2 mmol/L and 2hPG 8.9 mmol/L, with FCP 0.99 ng/ml and 2hCP 2.6 ng/ml. Both serum amylase and lipase were within the normal range. The proband's grandmother was diagnosed with diabetes at 51 years of age (BMI 25.3 kg/m2) and is now being treated with metformin. No test results for pancreatic enzymes and C-peptide were available. Diabetes was also diagnosed in the proband's uncle, who was in his thirties (BMI 26.9 kg/m2) and declined genetic testing. Two sisters of the proband's grandmother were also overweight diabetes, however no details of clinical features and genetic results were available (Figure 1).
Figure 1
This study was approved by the Ethics Committee of PUMCH, and informed consent was obtained from the proband and his family members. The proband underwent whole-exome detection by next-generation sequencing (NGS), which revealed a novel heterozygous missense mutation (NM_000209; c.463C>A) in the coding region, exon 2, of the PDX1 gene. This mutation was then verified by Sanger sequencing (Figure 2).
Figure 2
The father, mother and grandmother underwent Sanger sequencing for the target gene, and the same mutation was also detected in his father and grandmother. This mutation leads to a change in the amino acid sequence (p. Arg155Ser). The variant detected was not found in the 1000 Genomes and Exome Sequencing Project (ESP), and allele frequencies in the Exome Aggregation Consortium (ExAC) were 9.593 × 10−5. Both Mutationtaster (http://www.mutationtaster.org) and Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/) predicted this variant to be pathogenic. Based on the 2015 guidelines developed by the American College of Medical Genetics and Genomics (ACMG) () for the classification of pathogenic or likely pathogenic variants, the novel PDX1 mutation identified in this family was considered “likely pathogenic,” based on the evidence framework of PM1 (located in a mutational hot spot and/or critical and well-established functional domain without benign variation), PM2 (absent from controls in ESP, 1000 Genomes, or ExAC), PP1 (cosegregation with disease in multiple affected family members in a gene definitively known to causes the disease), and PP3 (multiple lines of computational evidence support a deleterious effect on the gene or gene product). A heterozygous mutation of HNF1α (NM_000545, c.1107+9C>G) was detected by NGS, which was considered BS1 based on ACMG. No other diabetes-related genes were found in the proband.
Discussion
MODY4 is caused by a mutation in the PDX1 gene (OMIM: 600733), which was first reported by Stoffers et al. (). Herein, we report a MODY4 family with a missense mutation in exon 2 of the PDX1 gene c.463C>A (p.Arg155Ser). To the best of our knowledge, this variant has been detected for the first time and is the first MODY4 pedigree in China.
In the pedigree of our report, all affected family members were overweight at diagnosis suggestive of T2D. However, the low level of FCP in his father indicated pancreatic endocrine dysfunction. Moreover, although the proband was overweight, no hyperinsulinemia was present. We suggest that the normal levels of FCP and 2hCP are most likely a consequence of obesity. Similarly, Fajans et al. () studied the genetic and clinical features of diabetic subjects in a five-generation Michigan-Kentucky pedigree and found that both MODY4 and T2D were associated with obesity and hyperinsulinemia. The author suggested that there was at least a partial compensatory response in these subjects. In fact, obesity and obesity-induced hyperinsulinemia have been observed in MODY1, MODY3, MODY4, and MODY6 (–). Obese MODY and T2D are phenotypically indistinguishable and can only be differentiated by genetic studies. Therefore, multigenerational obese diabetic subjects should not be excluded from genetic tests.
PDX1 appears to be a key regulator of islet peptide hormone expression and is also responsible for the development of the pancreas. Six families with heterozygous PDX1 variants related to MODY have been reported (, , –) without the exocrine function described in these studies. Pancreatic agenesis has only been reported in PDX1 mutated homozygosity () or compound heterozygosity (). However, Caetano et al. () recently described dorsal pancreatic agenesis in two Brazilian patients with MODY4, and one of them also had exocrine insufficiency. In our study, although no pancreatic agenesis was detected, the proband suffered from abdominal pain, and his serum lipase was slightly low, which characterizes exocrine pancreatic insufficiency. His father did not present with low pancreatic enzymes.
Stoffers et al. () suggested that the mechanism of diabetes in individuals with this mutation may be not only reduced gene dosage but also a dominant-negative inhibition of transcription of the insulin gene and other beta cell-specific genes regulated by the mutant IPF1. The variant in our cases is in the homeobox domain of IPF1 (http://www.ebi.ac.uk/interpro/). The homeobox domain is well-conserved in many animals. It binds DNA through a helix-turn-helix (HTH) structure. The HTH motif is characterized by two alpha helices, which make intimate contacts with the DNA and are joined by a short turn. PHYRE2 (http://www.sbg.bio.ic.ac.uk/~phyre2/html/page.cgi?id=index) predicts that this variant is in the first helix of the homeobox (Figure 3).
Figure 3
As the first helix helps to stabilize the structure in a homeobox domain, we further investigated the stability of this variant by MUpro software (http://mupro.proteomics.ics.uci.edu), which indicated that this variant leads to a decrease in stability (confidence score = −0.965). Therefore, we suspect that this variant is at least partly pathogenic because of the stability decrease of HTH, which may affect IPF1 binding to the INS gene. However, functional tests in vivo and vitro are necessary to establish pathogenicity.
In conclusion, this is the first report of MODY4 in a Chinese family, and we report a novel PDX1 mutation. Pancreatic endocrine insufficiency may be unmasked in PDX1-deficient diabetes with obesity, and genetic testing should be carried out in young early-onset obese diabetic patients with a family history of diabetes.
Statements
Data availability statement
The data for this study can be found in the NCBI Sequence Read Archive under accession number SRR9613620 (https://dataview.ncbi.nlm.nih.gov/object/SRR9613620).
Ethics statement
This study was approved by the Ethics Committee of PUMCH. All patients provided written informed consent to participate in the study, which was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. Written informed consent was obtained from the proband and his father for the publication of this case report.
Author contributions
MD collected the clinical data and wrote the manuscript. LZ and TW collected the clinical data and summarized the relevant literature. All the work was performed under the instructions of XX. All the authors have contributed significantly.
Funding
This work was supported by grants from the National Key R&D Program of China (2017YFC1309603), the National Key Research and Development Program of China (2016YFA0101002), and the National Natural Science Foundation of China (No. 81170736, 81570715).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
PihokerCGilliamLKEllardSDabeleaDDavisCDolanLMet al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab. (2013) 98:4055–62. 10.1210/jc.2013-1279
2.
LiuLLiuYGeXLiuXChenCWangYet al. Insights into pathogenesis of five novel GCK mutations identified in Chinese MODY patients. Metab Clin Exp. (2018) 89:8–17. 10.1016/j.metabol.2018.09.004
3.
AhlgrenUJonssonJJonssonLSimuKEdlundH. beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev. (1998) 12:1763–8. 10.1101/gad.12.12.1763
4.
StoffersDAFerrerJClarkeWLHabenerJF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet. (1997) 17:138–9. 10.1038/ng1097-138
5.
ClocquetAREganJMStoffersDAMullerDCWidemanLChinGAet al. Impaired insulin secretion and increased insulin sensitivity in familial maturity-onset diabetes of the young 4 (insulin promoter factor 1 gene). Diabetes. (2000) 49:1856–64. 10.2337/diabetes.49.11.1856
6.
SchwitzgebelVMMaminABrunTRitz-LaserBZaikoMMaretAet al. Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. J Clin Endocrinol Metab. (2003) 88:4398–406. 10.1210/jc.2003-030046
7.
RichardsSAzizNBaleSBickDDasSGastier-FosterJet al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. (2015) 17:405–24. 10.1038/gim.2015.30
8.
FajansSSBellGIPazVPBelowJECoxNJMartinCet al. Obesity and hyperinsulinemia in a family with pancreatic agenesis and MODY caused by the IPF1 mutation Pro63fsX60. Transl Res. (2010) 156:7–14. 10.1016/j.trsl.2010.03.003
9.
MaleckiMTJhalaUSAntonellisAFieldsLDoriaAOrbanTet al. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet. (1999) 23:323–8. 10.1038/15500
10.
GonsorcikovaLPruhovaSCinekOEkJPelikanovaTJorgensenTet al. Autosomal inheritance of diabetes in two families characterized by obesity and a novel H241Q mutation in NEUROD1. Pediatr Diabetes. (2008) 9(4 Pt 2):367–72. 10.1111/j.1399-5448.2008.00379.x
11.
WeintrobNSternEKlipper-AurbachYPhillipMGat-YablonskiG. Childhood obesity complicating the differential diagnosis of maturity-onset diabetes of the young and type 2 diabetes. Pediatr Diabetes. (2008) 9:60–4. 10.1111/j.1399-5448.2007.00259.x
12.
CockburnBNBermanoGBoodramLLTeelucksinghSTsuchiyaTMahabirDet al. Insulin promoter factor-1 mutations and diabetes in Trinidad: identification of a novel diabetes-associated mutation (E224K) in an Indo-Trinidadian family. J Clin Endocrinol Metab. (2004) 89:971–8. 10.1210/jc.2003-031282
13.
AnikACatliGAbaciASariEYesilkayaEKorkmazHAet al. Molecular diagnosis of maturity-onset diabetes of the young (MODY) in Turkish children by using targeted next-generation sequencing. J Pediatr Endocrinol Metab. (2015) 28:1265–71. 10.1515/jpem-2014-0430
14.
ChaplaAMruthyunjayaMDAshaHSVargheseDVarshneyMVasanSKet al. Maturity onset diabetes of the young in India - a distinctive mutation pattern identified through targeted next-generation sequencing. Clin Endocrinol. (2015) 82:533–42. 10.1111/cen.12541
15.
MangrumCRushEShivaswamyV. Genetically targeted dipeptidyl peptidase-4 inhibitor use in a patient with a novel mutation of MODY type 4. Clin Med Insights Endocrinol Diabetes. (2015) 8:83–6. 10.4137/CMED.S31926
16.
StoffersDAZinkinNTStanojevicVClarkeWLHabenerJF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet. (1997) 15:106–10. 10.1038/ng0197-106
17.
CaetanoLASantanaLSCosta-RiquettoADLerarioAMNeryMNogueiraGFet al. PDX1 -MODY and dorsal pancreatic agenesis: new phenotype of a rare disease. Clin Genet. (2018) 93:382–6. 10.1111/cge.13044
18.
StoffersDAStanojevicVHabenerJF. Insulin promoter factor-1 gene mutation linked to early-onset type 2 diabetes mellitus directs expression of a dominant negative isoprotein. J Clin Invest. (1998) 102:232–41. 10.1172/JCI2242
Summary
Keywords
MODY4, PDX1, pancreatic exocrine dysfunction, obese, Chinese
Citation
Deng M, Xiao X, Zhou L and Wang T (2019) First Case Report of Maturity-Onset Diabetes of the Young Type 4 Pedigree in a Chinese Family. Front. Endocrinol. 10:406. doi: 10.3389/fendo.2019.00406
Received
25 March 2019
Accepted
06 June 2019
Published
03 July 2019
Volume
10 - 2019
Edited by
Jan Polák, Charles University, Czechia
Reviewed by
Bente Berg Johansson, University of Bergen, Norway; Aaron Hanukoglu, Tel Aviv University, Israel
Updates
Copyright
© 2019 Deng, Xiao, Zhou and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xinhua Xiao xiaoxh2014@vip.163.com
This article was submitted to Diabetes, a section of the journal Frontiers in Endocrinology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.